

Effects of Intravenous Photobiomodulation Therapy in the Management of Patients with COVID-19

authors:

 Alireza Fatemi ¹,  Maryam Barati ²,  Zahra Razzaghi
²,  Reza Fekrazad ^{3, 4},  Fatemeh Sheibani ², 
Ehsan Kamani ²,  Mohammadreza Razzaghi ^{2, *},  Vahid
Mansouri ⁵,  Mohammad Barzegar ⁶,  Mehri
Javaherygallojeh ²

1 Infectious Diseases and Tropical Medicine Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran

2 Laser Application in Medical Sciences Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran

3 Radiation Sciences Research Center, AJA University of Medical Sciences, Tehran, Iran

4 International Network for Photo Medicine and Photo Dynamic Therapy (INPMPDT), Universal Scientific Education and Research, Network (USERN), Tehran, Iran

5 Proteomics Research Center, Faculty of Paramedical Sciences, Shahid

Beheshti University of Medical Sciences, Tehran, Iran

6 Department of English Language, School of Health Management and Information Sciences, Iran University of Medical Sciences, Tehran, Iran

* Corresponding Author: Laser Application in Medical Sciences Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran. Email: morezarazaghi@gmail.com

Archives of Clinical Infectious Diseases: [Vol.19, issue 1](#); e140556

published online: January 20, 2024

article type: Research Article

received: September 12, 2023

accepted: December 10, 2023

DOI: <https://doi.org/10.5812/archcid-140556>

how to cite: Fatemi A, Barati M, Razzaghi Z, Fekrazad R, Sheibani F, et al. Effects of Intravenous Photobiomodulation Therapy in the Management of Patients with COVID-19. Arch Clin Infect Dis. 2024;19(1):e140556. <https://doi.org/10.5812/archcid-140556>.

Abstract

Background:

The symptoms of coronavirus disease 2019 (COVID-19) range from asymptomatic to severe respiratory distress or death. Reviews on potential COVID-19 treatments show no established therapy. Photobiomodulation can help in reducing inflammation and speed up tissue repair. In addition, due to its few side effects, it appears to be effective in restricting COVID-19. Therefore, it was decided to use this method in disease control to achieve

the systemic impact of intravascular photobiomodulation therapy in this study.

Methods:

A total of 60 patients were randomly divided into three groups of 20 subjects: A control group that received common treatments for COVID-19, a group treated with a low-power gallium arsenide laser diode (660 nm) with an output dose of 2 J/cm^2 for 7 minutes and 5 days in a row in addition to standard treatments, and another group that received common treatments with the same laser dose at the same time as the first group with a low-power diode laser (450 nm). Laboratory data and clinical criteria between groups were compared before and after the treatment.

Results:

An increase in O_2 and partial pressure of oxygen (PO_2) was significant in the two laser therapy groups ($P < 0.05$). In addition, the partial pressure of carbon dioxide (PCO_2) decreased significantly in the blue laser group (mean difference = -1.44 ± 12.72). The COP score was reduced in all groups; however, only in the blue laser group the reduction in COP score was significant ($P < 0.05$). In the blue laser group, the COP score before and after the treatment was reduced.

Conclusions:

The use of an intravenous laser with red and blue wavelength with an output dose of 2 J/cm^2 for 7 minutes and 5 days in a row, in addition to standard treatments, showed the improvement of oxygenation (O_2 and PO_2 in arterial blood gas [ABG]) and the reduction of inflammatory factors (erythrocyte sedimentation rate [ESR] and C-reactive protein [CRP]) and COP scores. However, further extensive studies are needed to prove the therapeutic effects of intravenous lasers, along with the usual treatments for COVID-19.

Keywords

[COVID-19](#) [Intravenous Laser Therapy](#) [Low-Power Diode Laser](#) [Photobiomodulation](#) [Therapeutic Laser](#) [Low-Level Laser Therapy](#)

1. Background

Coronaviruses encompass an extensive variety of viruses that affect animal species. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes coronavirus disease 2019 (COVID-19), with manifestations varying from asymptomatic to severe acute respiratory distress syndrome (ARDS) to death (1, 2). Additionally, in severe cases of coronavirus infection, platelet damage and disturbed hemostasis are primary targets (3).

The coronavirus disease 2019 spread suddenly and caused the pandemic at the end of 2019. The disease had a high prevalence, and there was no definitive treatment. As a result, researchers have been looking for a novel and less invasive way to control the disease. However, recent reviews and meta-analyses of such treatment methods as remdesivir and nucleoside analogs, monoclonal antibodies, chloroquine (CQ) and its derivative hydroxychloroquine (HCQ), Chinese herbal medicine, convalescent plasma, and natural compounds in clinical and experimental studies have demonstrated that there is not a particular type of therapy for treating COVID-19 (4, 5).

Low-level laser therapy (LLLT) refers to a treatment modality that employs visible light and infrared laser radiation (wavelengths of 450–1200 nm). A low-intensity laser diode (< 500 mW) emits monochromatic light or a single wavelength. Low-level laser therapy is also called cold laser therapy or photobiomodulation therapy (6).

Low-level laser therapy can be anti-inflammatory, quicken cell proliferation, and reduce pain. Low-level laser therapy effects are caused by a photochemical reaction triggered by a photo-acceptor molecule in the cell,

which changes membrane permeability and metabolism. Opsins, calcium channels, cytochrome c oxidase, and water molecules are the main mediators of this process. Heat is not a factor (2). This leads to enhanced synthesis of messenger ribonucleic acid (mRNA) and cellular proliferation. Low-level laser therapy has been reported to induce the generation of reactive oxygen species (ROS) in normal cells. However, its effect on ROS levels is diminished in oxidatively stressed cells, as observed in animal disease models. Low-level laser therapy elicits an up-regulation of antioxidant defenses and a subsequent decrease in oxidative stress (7).

Published studies have revealed that LLLT controls antioxidant defenses and lowers ROS in cells under oxidative stress and animal models of disease. In pathological conditions, LLLT diminishes nuclear factor kappa B (NF- κ B), which is a protein complex controlling the transcription of deoxyribonucleic acid (DNA). Numerous investigations have demonstrated abatement in reactive nitrogen species and prostaglandins in diverse animal models (8).

The anti-inflammatory properties of LLLT in the context of lung inflammation have been validated through numerous experimental animal examinations. Low-level laser therapy alleviates cytokine storms at different levels and diminishes key provocative metabolites, including interleukin 6 (IL-6) and tumor necrosis factor-alpha (TNF- α). Although IL-6 antagonists are under investigation for the treatment of COVID-19, LLLT diminishes the generation of IL-6 in addition to the production of other chemokines and metabolites (9, 10).

While stimulating tissue healing and regeneration, LLLT functions against cytokine storms and ARDS. Experimental and animal models of lung diseases and infections have shown numerous molecular and cellular effects that are local and systemic. Photobiomodulation diminishes inflammation without altering pulmonary function in acute pulmonary diseases. This treatment treats inflammatory lung complications, such as chronic obstructive pulmonary disease (COPD) (11). The use of LLLT has been

proposed as a viable intervention for the management of pandemic coronavirus infections (11). The evidence from the literature supports the application of photobiomodulation to control COVID-19.

Low-level laser therapy has been utilized in the treatment of respiratory tract disorders since 1978. There are different methods for laser therapy, local and systemic, which can be referred to as whole-body irradiation or intravenous and transcutaneous methods. Intravenous laser blood irradiation therapy, also known as intravenous laser therapy or ILBI uses low levels of laser radiation to stimulate changes in the way molecules in the blood interact with each other. This therapy exposes the patient's blood to laser radiation. These changes include the interactions between lipid and water molecules, protein and water molecules, and lipid and protein molecules in the blood. The addition of intravenous LLLT of blood to conventional treatment has been shown to significantly enhance the bactericidal activity of neutrophils in cases of community-acquired pneumonia (8-10).

Low-level laser devices can be configured to target lung inflammation (12, 13). Low-level laser therapy represents fewer adverse effects and cost-effective modalities in contrast to alternative treatments and pharmaceutical agents, such as IL-6 antagonists. Low-level laser therapy has been demonstrated to be a secure, efficient, and cost-effective therapeutic modality with no observable side effects in contrast to other treatment options. Drawing from the available information, it appears that LLLT might expedite the process of convalescence from COVID-19, thereby expediting the process of getting patients off ventilator support and ultimately facilitating quicker discharge from the intensive care unit (ICU). The implementation of this measure could potentially alleviate the overwhelming burden on healthcare systems, which are currently experiencing a significant amount of tension (11).

Low-level laser therapy characteristics include the alleviation of inflammatory cytokines in cytokine storms, promotion of apoptosis of

inflammatory cells, and protection of alveolar cells from damage. These findings reveal that photobiomodulation could be an effective method for the management of ARDS and can be employed with the conventional treatment of COVID-19 at various stages of the disease (11).

Therefore, considering the above-mentioned issues, the current study aimed to compare the effect of two types of LLLT, intravenous (IV) red laser and IV blue laser, on the control and recovery of COVID-19 patients.

2. Methods

This randomized clinical trial assessed the effect of intravenous lasers on COVID-19 patients in Shohada-Tajrish Hospital, Shahid Beheshti University of Medical Sciences (SBMU), Tehran, Iran. The study protocol was approved by the Ethics on the Biomedical Research Committee of Shahid Beheshti University of Medical Sciences (registration code: IR.SBMU.RETECH.REC.1400.341) and registered in the Iranian Registry of Clinical Trials (IRCT: IRCT20111121008146N39).

A total of 60 patients who were admitted to the hospital (40 patients in the experimental groups receiving the intervention, 20 patients in the red laser group, 20 patients in the blue laser group, and 20 patients in the control group) with severe COVID-19 physical symptoms (e.g., difficulty breathing, constant pain or pressure in the chest, bluish face or lips, and sudden confusion) were included in this study. The COVID-19 patients were diagnosed with a positive RT-PCR test and radiological signs of COVID-19 on a computed tomography (CT) scan (diffuse alveolar damage). Written informed consent was obtained from all patients. The authors also explained that the information would remain confidential.

The patients with severe COVID-19 were hospitalized, and those who fulfilled the following criteria were included in this study: Saturation of peripheral oxygen (SpO_2) < 93% at sea level at room temperature, a ratio of

arterial oxygen partial pressure PaO₂ (in mm Hg) to fractional inspired oxygen (PaO₂/FiO₂) < 300 mm Hg, a respiratory rate of > 30 breaths/ min, or lung infiltrates > 50% (14-16). Patients under 30 years, patients with cancer or tumor comorbidities, and pregnant patients were not included in the study.

The eligible participants were assigned to each group with a block randomization method. Block randomization was conducted to randomize the sequence. All possible patterns of blocks were written and selected randomly. In the next step, 6 patients were filled in each block (2 patients in the red laser group, 2 patients in the blue laser group, and 2 patients in the control group). Both the intervention group and the control group were treated with conventional drugs and antibiotics according to the national guidelines of Iran. In the blue and red laser groups, photobiomodulation therapy was added to the common treatment.

In the IV laser method, laser light was directly irradiated into the blood via a sterile disposable catheter. Two millimeters of optical fiber was inserted and spread into the blood circulation. This method is similar to serum injection. The evaluations were carried out once before the treatment in the treatment groups and once at the end of the treatment.

The patients were treated with a low-power gallium arsenide laser diode (660 nm) with an output dose of 2 J/cm² for 7 minutes and 5 days in a row, similar to the same laser dose at the same time as the first group with a low-power diode laser (450 nm). Table 1 shows the laser parameters used in this experiment.

Table 1.

Laser Parameters

Laser Type Diode	Red IV Laser	Blue IV Laser
Wavelength (nm)	660	410

Power (mw)	100	100
Radiation area (mm)	Point (0.19)	Point (0.19)
Mode of radiation	Continues	Continues
Dose of radiation/second (J/cm ²)	2	2

Patient demographic data, smoking status, alcohol abuse, comorbidity of chronic diseases, and surgery history were collected at the beginning of the study. The number of breaths/minute, heart rate/minute, blood pressure (mm/hg), body temperature (celsius), percentage of oxygen saturation at rest (mm/hg), clinical symptoms, mortality, and need for respiratory equipment, ICU hospitalization rate, laboratory tests (complete blood count [CBC], C-reactive protein [CRP], creatine phosphokinase [CPK], lactate dehydrogenase [LDH], ferritin, erythrocyte sedimentation rate [ESR], lymphocytes, IL-6), and SMART-COP which is a tool for predicting a patient with community-acquired pneumonia were assessed before and after the intervention. SMART- COP evaluates the risk of admitting the patient to the ICU by total scores. Table 2 shows COP score severity risk factors and the calculation of the severity. Total SMART-COP points could range from 0 to 11 points, with 0 - 2, 3 - 4, 5 - 6, and 7 - 11 points indicating low risk, moderate risk, high risk, and very high risk, respectively (17).

Table 2.

COP Score Severity Index

Disease Severity Risk Factors	Points
Systolic blood pressure < 90 mmHg	2
Multiple lobes involved in the chest X-ray	1
Albumin levels less than 3.5 g/dL	1
Any age: Respiratory rate less than 25 breaths/minute	0
50 years old or younger: Respiratory rate 25 breaths/minute or more	1
Over 50 years old: Respiratory rate 30 breaths/minute or more	1

Tachycardia of 125 beats/minute or more	1
Confusion (acute)	1
Any age: PaO₂ ≥ 70 mmHg or O₂ saturation ≥ 94% or PaO₂/FiO₂ ≥ 333 if receiving O₂	0
50 years old or younger: PaO₂ < 70 mmHg or O₂ saturation ≤ 93% or PaO₂/FiO₂ < 333 if receiving O₂	2
Over 50 years old: PaO₂ < 60 mmHg or O₂ saturation ≤ 90% or PaO₂/FiO₂ < 250 if receiving O₂	2
pH (arterial) < 7.35	2

Data analysis was conducted using SPSS software (version 26; IBM Corp Released 2016, NY, USA). Frequency and percentages were utilized to describe the categorical variables. The mean $\pm$ standard deviation (SD) and 95% confidence interval (CI) were used to describe the quantitative variables. The normality of quantitative variables was tested with the Shapiro-Wilks test. The paired-sample *t*-test and the analysis of variance (ANOVA) test were employed to compare the mean differences in quantitative outcomes within and between the groups. Furthermore, the Chi-square test was used to assess categorical outcomes. The analysis was performed on completed data (without any missing data). Two-tailed tests were employed to interpret all P-values, and a P-value less than 0.05 was considered statistically significant.

3. Results

In this study, 28 males (46.7%) and 32 females (53.3%) were evaluated. The mean age of patients was 47.32 ± 11.57 years. A total of 60 COVID-19 patients were divided into three groups equally. The patients' mean age was 45.76 ± 11.78 , 44.25 ± 10.12 , and 51.74 ± 9.87 in the red laser, blue laser, and control groups, respectively ($P = 0.076$). Male to female ratio was 10 (50%)/10 (50%) in the red group, 10 (50%)/10 (50%) in the blue laser group, and 8 (40%)/12 (60%) in the control group ($P = 0.765$). None of the patients in each group had a history of cardiovascular or neurologic disease. Two

patients (10%) in the control group died ($P = 0.126$). Two patients (10%) in the control group and one patient (5%) in the blue laser group were referred to an ICU ($P = 0.349$).

The comparison of the fever and pulse rate before and after the study did not significantly change in each group. The evaluation of the pulmonary function of patients in each group before and after the study is shown in Table 3. The mean percentage of lung involvement had a reduction in all groups; nevertheless, 4 patients (20%) in the control group, 1 patient (5%) in the red laser group, and 2 patients (10%) in the blue laser group had severe score lung involvement after the treatment ($P = 0.322$). In addition, one patient in the control group had a lung involvement score increase from 40% to 60%. The mean reduction of lung involvement in the red group was more than in other groups ($P = 0.001$).

Table 3.

Comparison of the Pulmonary Function of Patients in Each Group Before and After the Study

Variables	Red Laser	Blue Laser	Control	P-Value
CT involvement				
Before	47.00 ± 13.01	42.00 ± 12.39	42.37 ± 14.37	0.414
After	26.25 ± 12.02	29.75 ± 11.29	31.84 ± 17.73	0.665
Mean difference	-20.75 ± 10.29	-12.25 ± 4.72	-10.53 ± 8.95	0.0001
P-value	0.0001	0.0001	0.002	
SMART-COP score				
Before	3.0 ± 0.65	2.30 ± 0.73	3.25 ± 0.55	0.0001
After	2.95 ± 0.95	1.75 ± 0.96	2.90 ± 1.16	0.001
Mean difference	-0.05 ± 1.05	-0.55 ± 0.99	-0.35 ± 1.26	0.748
P-value	0.666	0.026	0.265	
O₂				

Before	53.69 ± 19.91	44.99 ± 20.93	58.72 ± 19.29	0.100
After	76.70 ± 14.88	65.41 ± 18.62	70.92 ± 15.63	0.104
Mean difference	23.01 ± 22.75	20.41 ± 22.38	12.20 ± 23.80	0.161
P-value	0.001	0.003	0.067	
PO₂				
Before	31.83 ± 17.37	31.09 ± 31.51	32.03 ± 11.69	0.128
After	47.44 ± 13.96	35.56 ± 10.44	41.26 ± 15.28	0.025
Mean difference	15.62 ± 22.17	4.47 ± 30.57	9.23 ± 20.09	0.161
P-value	0.002	0.008	0.067	
PCO₂				
Before	46.95 ± 7.47	39.70 ± 7.75	48.93 ± 10.81	0.004
After	45.51 ± 10.32	40.74 ± 6.19	50.88 ± 5.36	0.0001
Mean difference	-1.44 ± 12.72	1.03 ± 8	1.95 ± 12.53	0.619
P-value	0.617	0.570	0.494	
O₂ Saturation				
Before	91.76 ± 3.03	91.73 ± 5.27	90.10 ± 2.26	0.114
After	93.64 ± 2.78	93.68 ± 3.60	92.50 ± 3.83	0.544
Mean difference	-1.88 ± 2.11	-2.37 ± 3.57	-2.95 ± 4.69	0.388
P-value	0.007	0.016	0.003	

The mean COP score was reduced significantly in the blue laser group. The mean of O₂ and PO₂ had a significant increase in the blue and red laser groups. The PCO₂ mean had a reduction only in the red laser group (-1.44 ± 12.72); nevertheless, the mean difference was not significant in three group comparisons (P > 0.05). O₂ saturation decreased significantly in all groups (P < 0.05), and no significant difference was observed between the three groups. The laboratory index was compared within and between each group, as reported in Table 4.

Table 4.

Comparison of Laboratory Findings/Variables Before and After the Study in Each Group

Variables	Red Laser	Blue Laser	Control	P-Value
WBC				
Before	6.97 ± 4.22	6.24 ± 4.26	6.71 ± 3.55	0.480
After	9.19 ± 3.83	10.22 ± 3.24	9.25 ± 2.70	0.324
P-value	0.046	0.001	0.001	
Lymphocyte				
Before	17.60 ± 10.34	18.75 ± 8.61	17.80 ± 7.71	0.774
After	15.10 ± 7.52	14.80 ± 6.61	11.65 ± 6.09	0.133
P-value	0.935	0.141	0.007	
PLT				
Before	180.65 ± 62.33	176.95 ± 76.09	202.90 ± 85.67	0.315
After	288.70 ± 118.126	287.45 ± 89.70	275.95 ± 102.77	0.954
P-value	0.0001	0.0001	0.002	
ESR				
Before	22.07 ± 11.47	45.28 ± 28.72	34.0 ± 17.89	0.068
After	25.71 ± 14.42	33.50 ± 20.56	35.14 ± 24.74	0.589
P-value	0.730	0.045	0.950	
CRP				
Before	33.73 ± 19.27	73.17 ± 31.43	38.86 ± 31.41	0.001
After	37.01 ± 35.23	27.75 ± 29.27	39.75 ± 30.83	0.246
P-value	0.845	0.002	0.795	
BUN				
Before	16.95 ± 6.06	29.25 ± 12.72	19.45 ± 9.52	0.001
After	19.55 ± 5.59	38.81 ± 10.96	24.40 ± 12.95	0.0001
P-value	0.011	0.0001	0.023	
Cr				
Before	1.11 ± 0.19	1.01 ± 0.25	1.09 ± 0.36	0.264

After	0.96 ± 0.18	0.95 ± 0.19	1.02 ± 0.21	0.622
P-value	0.001	0.046	0.062	
PH				
Before	7.38 ± 0.05	7.40 ± 0.04	7.39 ± 0.05	0.640
After	7.36 ± 0.05	7.41 ± 0.03	7.36 ± 0.05	0.0001
P-value	0.093	0.364	0.019	
HCO₃				
Before	26.11 ± 2.56	24.44 ± 2.79	28.11 ± 4.32	0.006
After	25.28 ± 5.48	26.09 ± 2.77	29.03 ± 4.69	0.001
P-value	2.83 ± 6.64	-1.65 ± 2.71	-0.93 ± 1.33	0.01
BE				
Before	2.92 ± 1.72	1.27 ± 0.74	3.32 ± 2.82	0.003
After	3.31 ± 3.53	2.16 ± 1.57	4.20 ± 3.24	0.115
P-value	0.852	0.047	0.185	

4. Discussion

The definitive treatment for COVID-19 does not exist to date.

Photobiomodulation dramatically reduces the number of cells that cause inflammation and the release of chemicals that promote inflammation in the lung and reduce the amount of collagen buildup and the presence of the P2X7 receptor. Therefore, photobiomodulation is a hopeful remedy for other lung illnesses, such as COVID-19 (12). In addition, spending a long time on ventilators can harm the lungs and make the disease worse. Low-level laser therapy can be used to reduce this unwanted adverse effect. This was proven in experiments with rats, where using LLLT had a positive effect by reducing lung injury and lowering neutrophil counts in different parts of the lungs. Patients who are on ventilators need to have their inflammatory factors controlled and their healing process supported in order to be able to stop using ventilators. Therefore, LLLT is a method that is safe and noninvasive. It has been used for many years to treat pain, help wounds heal,

and help with health problems, such as diseases in the lungs. Therefore, photobiomodulation, along with regular medical care, can be a good way to improve the effectiveness of treatments, lessen inflammation, help with healing, and make recovery faster (11, 17).

According to the findings of the present study, the intravascular photobiomodulation method has been used less, and this study was aimed at investigating its auxiliary effects in combination with the usual COVID-19 treatment method. Furthermore, two laser therapy groups were compared to the control group. An increase in O_2 and PO_2 was significant in the two laser therapy groups. In addition, PCO_2 decreased significantly in the blue laser group. When CO_2 constructions are low, the affinity of hemoglobin for O_2 is increased. Therefore, this issue justifies the increase in O_2 and PO_2 in the laser group.

In three studies about the role of photobiomodulation in the treatment of COVID-19, the results of the current study regarding the positive effect of blue lasers have been investigated. The aforementioned studies show blue light positive impacts, such as the inactivation of viruses (counting coronaviruses and common flu viruses) and antibacterial effects. These impacts can be employed separately to clean, prevent the spread of coronavirus from tainted surfaces, and diminish microscopic organisms within the treatment of COVID-19 (18-20). The blue laser has multiple benefits beyond being antimicrobial and anti-inflammatory. NO is crucial for immune function, and the laser increases its production, leading to increased mitochondrial biogenesis and oxygen connection to red blood cells (21-23).

In a recent study, the COP score was reduced in all groups. In the blue laser group, the mean score before and after the treatment changed from a moderate risk (3 to 4 points) to a low risk (0 to 2 points). Moreover, the COP score in the blue laser therapy group decreased more than in the other groups ($P = 0.026$). However, the difference between the other two groups was not notable. It seems that laser treatment is more effective in patients

who are at a certain level of severity of the disease, and it is better to stratify the severity of the disease before starting LLLT (11).

An article reported that the use of adjunctive photobiomodulation therapy in the early phases of severe ARDS observed in patients with COVID-19 could accelerate recovery and reduce the need for long-term ventilator support and ICU stay. Oxygen saturation (SpO_2) rose from 93-94% to 97 - 100%, and oxygen demand diminished from 2-4 L/min to 1 L/min. Additionally, SMART-COP declined from 4 to 0. C-reactive protein normalized from 15.1 to 1.23 (10). In the present study, no mortalities were observed in the laser treatment groups. One person in the blue laser group, who had a low O_2 saturation level at the beginning, was transferred to the ICU. It seems that the reason for the lack of complete recovery of oxygen saturation compared to other articles is the short duration of the study.

The white blood cells (WBC) were reduced; however, in all groups, the mean WBC increased after 5 days. Increasing the mean WBC number after a short time can be related to the involvement of other body organs, such as kidneys and the digestive system, during systemic infection.

The use of LLLT has been proven to reduce inflammation in the lungs in animals used in experiments. Photobiomodulation mitigates cytokine storm at various levels and diminishes the key inflammatory metabolites, including IL-6 and $\text{TNF-}\alpha$. Interleukin 6 antagonists are being examined for the treatment of COVID-19. However, LLLT decreases the generation of IL-6 and reduces the production of other chemokines and metabolites (8, 9). Since IL-6 is one of the causes of inflammatory symptoms, such as fever, in patients and LLLT has the opposite effect on its activity, the reduction of fever in the treatment group is justified.

Research conducted on Russians has shown that IV (intravenous) treatment increases the amount of oxygen in their bodies and reduces the level of carbon dioxide. Furthermore, IV treatment stimulates oxygenation, reduces the lack of oxygen in tissues, boosts the body's defense against infections,

and regulates tissue function. Intravenous treatment decreases CRP content, increases complement activity, reduces thrombocyte aggregation ability, increases the levels of certain antibodies in the blood, and activates fibrinolysis, enhancing peripheral circulation (8). In this study, there was a significant CRP reduction in the blue laser group, and it seems that these effects might be able to justify the effects obtained from the aforementioned study (24).

There is no cure or complication-free treatment for COVID-19, as mentioned above. Therefore, any possible model that can help reduce and restore systemic or other damaged tissues can advance the treatment of adjuvant patients. More studies are required to show its effect on reducing the length of hospitalization, lung involvement, and mortality. It is suggested that the number of laser sessions and duration of laser treatment be increased in future studies.

4.1. Conclusions

In the current study, the use of an intravenous laser with red and blue wavelength with an output dose of 2 J/cm^2 for 7 minutes and 5 days in a row, in addition to common treatments, showed the improvement of oxygenation (O_2 and PO_2 in arterial blood gas [ABG]) and the reduction of inflammatory factors (ESR and CRP) and COP scores.

Footnotes

- **Authors' Contribution:** Study concept and design: Alireza Fatemi; acquisition of the data: Mehri Javahery Gallojeh; analysis and interpretation of the data: Maryam Barati and Vahid Mansouri; drafting of the manuscript: Fatemeh Sheibani, Mohammad Barzegar Rahatlou, and Maryam Barati; critical revision of the manuscript for important intellectual content: Reza Fekrazad; statistical analysis: Zahra Razzaghi; administrative, technical, and material support: Mohammadreza

Razzaghi and Ehsan Kamani; study supervision: Alireza Fatemi and
Mohammadreza Razzaghi

- **Clinical Trial Registration Code:** IRCT20111121008146N39.
- **Conflict of Interests:** There is no relationship with the industry, and the authors have no conflict of interest to disclose.
- **Data Availability:** The dataset presented in the study is available on request from the corresponding author during submission or after publication. The data are not publicly available.
- **Ethical Approval:** [IR.SBMU.RETECH.REC.1400.341](https://www.researchprotocols.org/2022/1/e341) .
- **Funding/Support:** All the authors declare any funding for the present manuscript.
- **Informed Consent:** Written informed consent was obtained from all patients.

References

1.

McIntosh K, Perlman S. Coronaviruses, Including Severe Acute Respiratory Syndrome (SARS) and Middle East Respiratory Syndrome (MERS). *Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases*. 2015. p. 1928-1936.e2. <https://doi.org/10.1016/b978-1-4557-4801-3.00157-0>.

2.

Zhu Z, Lian X, Su X, Wu W, Marraro GA, Zeng Y. From SARS and MERS to COVID-19: a brief summary and comparison of severe acute respiratory infections caused by three highly pathogenic human coronaviruses. *Respir Res.* 2020;**21**(1):224. [PubMed ID: [32854739](#)]. [PubMed Central ID: [PMC7450684](#)]. <https://doi.org/10.1186/s12931-020-01479-w>.

3.

Zamanian-Azodi M, Arjmand B, Razzaghi M, Tavirani MR, Ahmadzadeh A,

Rostaminejad M. Platelet and haemostasis are the main targets in severe cases of COVID-19 infection; a system biology study. *Archives Academic Emergency Med.* 2021;**9**(1).

4.

Han F, Liu Y, Mo M, Chen J, Wang C, Yang Y, et al. Current treatment strategies for COVID-19 (Review). *Mol Med Rep.* 2021;**24**(6). [PubMed ID: [34664677](#)]. [PubMed Central ID: [PMC8548951](#)].
<https://doi.org/10.3892/mmr.2021.12498>.

5.

Rajnik M, Cascella M, Cuomo A, Dulebohn SC, Di Napoli R. Features, evaluation, and treatment of coronavirus (COVID-19). *Uniformed Serv Uni Health Sci.* 2021.

6.

Fekrazad R. Photobiomodulation and Antiviral Photodynamic Therapy as a Possible Novel Approach in COVID-19 Management. *Photobiomodul Photomed Laser Surg.* 2020;**38**(5):255-7. [PubMed ID: [32326830](#)].
<https://doi.org/10.1089/photob.2020.4868>.

7.

Dominguez A, Velasquez SA, David MA. Can Transdermal Photobiomodulation Help Us at the Time of COVID-19? *Photobiomodul Photomed Laser Surg.* 2020;**38**(5):258-9. [PubMed ID: [32330404](#)].
<https://doi.org/10.1089/photob.2020.4870>.

8.

KazemiKhoo N, Ansari F. Blue or red: Which intravascular laser light has more effects in diabetic patients? *Lasers Med Sci.* 2015;**30**(1):363-6. [PubMed ID:

[25304768](https://doi.org/10.1007/s10103-014-1672-7)]. <https://doi.org/10.1007/s10103-014-1672-7>.

9.

Kazemi Khoo N, Iravani A, Arjmand M, Vahabi F, Lajevardi M, Akrami SM, et al. A metabolomic study on the effect of intravascular laser blood irradiation on type 2 diabetic patients. *Lasers Med Sci*. 2013;**28**(6):1527-32. [PubMed ID: [23358875](https://pubmed.ncbi.nlm.nih.gov/23358875/)]. <https://doi.org/10.1007/s10103-012-1247-4>.

10.

Kazemikhoo N, Sarafnejad AF, Ansari F, Mehdipour P. Modifying effect of intravenous laser therapy on the protein expression of arginase and epidermal growth factor receptor in type 2 diabetic patients. *Lasers Med Sci*. 2016;**31**(8):1537-45. [PubMed ID: [27406711](https://pubmed.ncbi.nlm.nih.gov/27406711/)]. <https://doi.org/10.1007/s10103-016-2012-x>.

11.

Sigman SA, Mokmeli S, Monici M, Vetrici MA. A 57-Year-Old African American Man with Severe COVID-19 pneumonia who responded to supportive photobiomodulation therapy (PBMT): First use of PBMT in COVID-19. *Am J Case Rep*. 2020;**21**. e926779. [PubMed ID: [32865522](https://pubmed.ncbi.nlm.nih.gov/32865522/)]. [PubMed Central ID: [PMC7449510](https://pubmed.ncbi.nlm.nih.gov/PMC7449510/)]. <https://doi.org/10.12659/AJCR.926779>.

12.

Da Cunha Moraes G, Vitoretti LB, De Brito AA, Alves CE, De Oliveira NCR, Dos Santos Dias A, et al. Low-level laser therapy reduces lung inflammation in an experimental model of chronic obstructive pulmonary disease involving P2X7 receptor. *Oxid Med Cell Longev*. 2018;**2018**:6798238. [PubMed ID: [29686745](https://pubmed.ncbi.nlm.nih.gov/29686745/)]. [PubMed Central ID: [PMC5857317](https://pubmed.ncbi.nlm.nih.gov/PMC5857317/)]. <https://doi.org/10.1155/2018/6798238>.

13.

De Brito AA, Da Silveira EC, Rigonato-Oliveira NC, Soares SS, Brandao-Rangel MAR, Soares CR, et al. Low-level laser therapy attenuates lung inflammation and airway remodeling in a murine model of idiopathic pulmonary fibrosis: Relevance to cytokines secretion from lung structural cells. *J Photochem Photobiol B*. 2020;**203**:111731. [PubMed ID: [31935633](#)]. <https://doi.org/10.1016/j.jphotobiol.2019.111731>.

14.

Mittal R, Chourasia N, Bharti VK, Singh S, Sarkar P, Agrawal A, et al. Blood-based biomarkers for diagnosis, prognosis, and severity prediction of COVID-19: Opportunities and challenges. *J Family Med Prim Care*. 2022;**11**(8):4330-41. [PubMed ID: [36352911](#)]. [PubMed Central ID: [PMC9638655](#)]. https://doi.org/10.4103/jfmipc.jfmipc_2283_21.

15.

Cobre AF, Stremel DP, Noleto GR, Fachi MM, Surek M, Wiens A, et al. Diagnosis and prediction of COVID-19 severity: Can biochemical tests and machine learning be used as prognostic indicators? *Comput Biol Med*. 2021;**134**:104531. [PubMed ID: [34091385](#)]. [PubMed Central ID: [PMC8164361](#)]. <https://doi.org/10.1016/j.compbimed.2021.104531>.

16.

Bennett TD, Moffitt RA, Hajagos JG, Amor B, Anand A, Bissell MM, et al. The National COVID Cohort Collaborative: Clinical characterization and early severity prediction. *MedRxiv*. 2021.

17.

Charles PG, Wolfe R, Whitby M, Fine MJ, Fuller AJ, Stirling R, et al. SMART-COP: A tool for predicting the need for intensive respiratory or vasopressor support in community-acquired pneumonia. *Clin Infect Dis*. 2008;**47**(3):375-84. [PubMed ID: [18558884](#)]. <https://doi.org/10.1086/589754>.

18.

Raeiszadeh M, Adeli B. A Critical Review on Ultraviolet Disinfection Systems against COVID-19 outbreak: Applicability, validation, and safety considerations. *ACS Photonics*. 2020;**7**(11):2941-51. [PubMed ID: [37556269](#)]. <https://doi.org/10.1021/acsp Photonics.0c01245>.

19.

Hanna R, Dalvi S, Salagean T, Bordea IR, Benedicenti S. Phototherapy as a Rational Antioxidant Treatment Modality in COVID-19 Management; New Concept and Strategic Approach: Critical Review. *Antioxidants (Basel)*. 2020;**9**(9). [PubMed ID: [32947974](#)]. [PubMed Central ID: [PMC7555229](#)]. <https://doi.org/10.3390/antiox9090875>.

20.

Walski T, Drohomirecka A, Bujok J, Czerski A, Waz G, Trochanowska-Pauk N, et al. Low-level light therapy protects red blood cells against oxidative stress and hemolysis during extracorporeal circulation. *Front Physiol*. 2018;**9**:647. [PubMed ID: [29904353](#)]. [PubMed Central ID: [PMC5991292](#)]. <https://doi.org/10.3389/fphys.2018.00647>.

21.

Iser BPM, Sliva I, Raymundo VT, Poletto MB, Schuelter-Trevisol F, Bobinski F. Definição de caso suspeito da COVID-19: Uma revisão narrativa dos sinais e sintomas mais frequentes entre os casos confirmados. *Epidemiologia e Serviços de Saúde*. 2020;**29**.

22.

Razzaghi MD, Kamani E. Role low-power blue laser with a wavelength of 405 nm in increasing the level of nitric oxide in increasing the resistance of cells to the virus (COVID-19) and its effect on virus (COVID-19) mortality in vitro.

23.

Jahani Sherafat S, Mokmeli S, Rostami-Nejad M, Razaghi Z, Rezaei Tavirani M, Razzaghi M. The Effectiveness of Photobiomodulation Therapy (PBMT) in COVID-19 Infection. *J Lasers Med Sci*. 2020;**11**(Suppl 1):S23-9. [PubMed ID: [33995965](https://pubmed.ncbi.nlm.nih.gov/33995965/)]. [PubMed Central ID: [PMC7956025](https://pubmed.ncbi.nlm.nih.gov/PMC7956025/)].
<https://doi.org/10.34172/jlms.2020.S4>.

24.

Brill GE, Gasparyan LV, Makela AM. 122 modification in relationships in the system endothelial cell blood platelet by low level laser irradiation. *Photodiagnosis and Photodynamic Therapy*. 2008;**5**:S40-1.
[https://doi.org/10.1016/s1572-1000\(08\)70124-8](https://doi.org/10.1016/s1572-1000(08)70124-8).

Copyright

Copyright © 2024, Fatemi et al. This open-access article is available under the Creative Commons Attribution 4.0 (CC BY 4.0) International License (<https://creativecommons.org/licenses/by/4.0/>), which allows for unrestricted use, distribution, and reproduction in any medium, provided that the original work is properly cited.

comments

Leave a comment here: